Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Bookworm28on Nov 30, 2021 6:08pm
101 Views
Post# 34182580

RE:Taking PMN Private

RE:Taking PMN Private
DavidKingCanada wrote:

As of today the Market Cap is less than 70 Million CAD. 

If they wanted to take it Private they could Sell the Company now or are they waiting to completely dilute the Shares and then Buy Back all Shares at a massive Discount.

Once again the SP is decreasing, don't be surprised if we see below 10 cents yet again. This is an excellent entry point as the SP will come near 20 cents before any Consolidation. 



IMO mgmt has a pretty good thing going as a public company. Can't see them going private. Can't see them raising funds as easily as a private company, without having so much as a phase I clinical trial under their belt:

https://clinicaltrials.gov/ct2/search/advanced?cond=&term=&cntry=&state=&city=&dist=

Let me know if I missed their phase I

Looking at the CVs of their mgmt/directors, they have around 300 years of combined experience. I'm a bit puzzled as to why they haven't been able to get the ball over the line - e.g. some clinical trials. Is the concept too complex to execute on?

Kind of curious to see what the consolidation ratio is.... "consolidate the common shares of the company within a range from a ratio of one postconsolidation common share for 30 preconsolidation common shares to up to a ratio of one postconsolidated common share for 60 preconsolidation common shares."

Still waiting for a buying opportunity, where the stock is cheap enough to offset the risk. I can't wait another 300 years worth of experience however. Just kiddin ;-), but you get the idea. GLTA.



<< Previous
Bullboard Posts
Next >>